KR920703102A - 인간 면역결핍 바이러스(human immunodeficiency virus)에 대한 항체와 선택적으로 반응하는 폴리펩타이드 및 그를 함유하는 백신(vaccines) - Google Patents
인간 면역결핍 바이러스(human immunodeficiency virus)에 대한 항체와 선택적으로 반응하는 폴리펩타이드 및 그를 함유하는 백신(vaccines)Info
- Publication number
- KR920703102A KR920703102A KR1019920701393A KR920701393A KR920703102A KR 920703102 A KR920703102 A KR 920703102A KR 1019920701393 A KR1019920701393 A KR 1019920701393A KR 920701393 A KR920701393 A KR 920701393A KR 920703102 A KR920703102 A KR 920703102A
- Authority
- KR
- South Korea
- Prior art keywords
- hiv
- amino acid
- acid sequence
- protein
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920001184 polypeptide Polymers 0.000 title claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 9
- 241000725303 Human immunodeficiency virus Species 0.000 title claims description 8
- 229960005486 vaccine Drugs 0.000 title claims description 6
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 239000000523 sample Substances 0.000 claims 5
- 238000009169 immunotherapy Methods 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 230000036436 anti-hiv Effects 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 230000002637 immunotoxin Effects 0.000 claims 3
- 229940051026 immunotoxin Drugs 0.000 claims 3
- 239000002596 immunotoxin Substances 0.000 claims 3
- 231100000608 immunotoxin Toxicity 0.000 claims 3
- 239000000758 substrate Substances 0.000 claims 3
- 102000006395 Globulins Human genes 0.000 claims 2
- 108010044091 Globulins Proteins 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 102000005936 beta-Galactosidase Human genes 0.000 claims 1
- 108010005774 beta-Galactosidase Proteins 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/974—Aids related test
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/22—Viral peptide or viral protein
- Y10S930/221—Retrovirus related, or human immunodeficiency virus related, or simian immunodeficiency virus related
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Laminated Bodies (AREA)
- Adhesives Or Adhesive Processes (AREA)
Abstract
내용 없음
Description
인간 면역결핍 바이러스(HUMAN IMMUNODEFICIENCY VIRUS)에 대한 항체와 선택적으로 반응하는 폴리펩타이드 및 그를 함유하는 백신(VACCINES)
[도면의 간단한 설명]
제1도는 HIV88(제1a도), HlV500(제1b도), HIV582(제1c도) 및 HlV647(제1d)을 위한 올리고뉴클레오티드 서열 코딩(coding) 을 도시한 것이다.
제2도는 SIV88(제2a도), SIV500 (제2b도), SIV582(제2c도) 및 SIV647(제2d도)에 대해 코딩하는 올리고뉴클레오티드 서열을 도시한 것이다.
제1도 및 제2도에서, 각각의 폴리펩타이드를 위한 인코드(encode)된 아미노산이 제한 엔도뉴클레아제를 위한 인식부위인 것 처럼 도시되었고 각 부위가 위에 표시되었는데 HIV-1 게놈(genome)으로 부터 올리고뉴클레오티드를 얻는데 사용될 수 있다.
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (18)
- 아미노산 서열과 폴리펩타이드 서열이 용융단백질에 뼈대를 포함하도록 NVTENFNMWKN, KAKRRVVQREKRAVG, ERYLKDQQLLGIWGCSGKLIC 와 EESQNQQEKNEQELLELDKWA로 이루어진 군으로 부터 선택된 아미노산 서열 및 비 HIV 폴리펩타이드 서열로 이루어진 용융단백질을 포함하는데 상기 용융 단백질이 HIV 양성 혈청과 반응함을 특징으로 하는 용융단백질.
- 제1항에 있어서, 상기 아미노산 서열이 상기 플리펩타이드 서열의 N말단에 펩타이드 결합으로 결합됨을 특징으로 하는 용융단백질.
- 제2항에 있어서, 상기 폴리펩타이드 서열이 β-갈락토시다제의 서열을 포함하는 것을 특징으로 하는 용융단백질.
- NVTENFNMWKN, KKAKRRVVQREKRAVG, ERYLKDQQLLGIWGCSGKLIC와 EESQNQQEKNEQELLELDKWA로 이루어진 그룹으로 부터 선택된 아미노산 서열을 포함하는 폴리펩타이드를 발현하는 것을 특징으로 하는 자기복제세포.
- (A) 아미노산 서열이 기질의 표면과 접촉하는 항체에 가까이 할 수 있도록 아미노산 서열 ERYLKDQQLLGIWGCSGKLIC과 비 HIV 폴리펩타이드 서열을 포함하는 용융단백질을 고체기질에 고정시키고, (B) 상기 기질의 표면과 접촉하도록 샘플을 위치시키고 (C) HIV 특이항체의 결합을 위한 상기 표면을 모니터하는 단계를 포함하는 샘플에서 항 HIV 항체의 존재를 검출하기 위한 진단학적 평가법.
- 제5항에 있어서, (C) 단계가 통상의 호울 바이러스 웨스턴 블롯평가법을 이용하여 테스트할때 HIV 음성을 시험하는 샘플에서 항 HIV 항체의 존재를 검출하는 것을 포함하는 진단학적 평가법.
- (A) 아미노산 서열 ERYLKDQQLIGlWGCSGKLIC과 효소의 아미노산 서열을 포함하는 용융단백질을 제공하고, (B) 액체내에서 용융단백질과 샘풀을 조합시키며, (C) 효소활성의 변조를 위한 조합을 모니터 하는 단계를 포함하는 샘풀에서 항 HIV 항체의 존재를 검출하기 위한 진단학적 평가법.
- 제1항에 의한 용융단백질과 무균의 약제학적으로 수용가능한 캐리어를 포함하는 것을 특징으로 하는 백신.
- 제8항에 의한 면역자극적인 양의 백신을 피검자에게 투여하는 단계를 포함하는 것을 특징으로 하는 면역요법.
- 제9항에 있어서, 백신이 투여될때 피검자가 이미 HIV-1에 감염된 것을 특징으로 하는 면역요법.
- HIV-1에 대하여 향하는 항체를 함유하는 초면역 글로블린이 생성되도록 제8항에 의한 백신으로 플라즈마 공급체를 면역시키는 단계를 포함하는 것을 특징으로 하는 HIV 감염에 대한 면역치료적 제제를 제조하는 방법.
- 제11항에 의해 제조된 면역자극적인 약의 초면역 글로블린을 피검자에게 투여하는 단계를 포함하는 것을 특징으로 하는 면역치료방법.
- 제1항에 의한 용융단백질에 대하여 향하는 항체를 HIV-1에 감염된 피검자에게 투여하는 단계를 포함하는데 상기 항체가 면역독소에 콘쥬게이트되는 것을 특징으로 하는 면역치료 방법.
- 면역독소에 콘쥬게이트된 제1항에 의한 용융단백질을 포함하는 것을 특징으로 하는 면역독소 콘쥬게이트.
- 기본적으로 제1항에 의한 용융단백질을 결합하는 항체로 이루어진 것을 특징으로 하는 조성물.
- 제15항에 있어서, 상기 조성물이 모노클로날 항체 조성물인 것을 특징으로 하는 조성물.
- 제15항에 있어서, 상기 항체는 HIV-1에 감염된 인간 피검자로 부터 생물학적 샘플을 제공하는 단계를 포함하는 공정에 의해서 얻어지지 않는 것을 특징으로 하는 조성물.
- ※ 참고사항:최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/450,150 US6248574B1 (en) | 1989-12-13 | 1989-12-13 | Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides |
| US450,150 | 1989-12-13 | ||
| PCT/US1990/007210 WO1991009872A1 (en) | 1989-12-13 | 1990-12-13 | Hiv-1 env fragment fusion protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR920703102A true KR920703102A (ko) | 1992-12-17 |
Family
ID=23786972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019920701393A Withdrawn KR920703102A (ko) | 1989-12-13 | 1990-12-13 | 인간 면역결핍 바이러스(human immunodeficiency virus)에 대한 항체와 선택적으로 반응하는 폴리펩타이드 및 그를 함유하는 백신(vaccines) |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6248574B1 (ko) |
| EP (1) | EP0509006A1 (ko) |
| JP (1) | JPH05503926A (ko) |
| KR (1) | KR920703102A (ko) |
| AU (1) | AU653926B2 (ko) |
| CA (1) | CA2071858A1 (ko) |
| IL (1) | IL96647A0 (ko) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6479055B1 (en) * | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
| US20070202127A1 (en) * | 1993-06-07 | 2007-08-30 | Duke University | Nucleic acids encoding DP-178 and other viral fusion inhibitor peptides useful for treating aids |
| US7358334B1 (en) | 2003-11-14 | 2008-04-15 | Jay W Chaplin | B cell-targeted toxins for humoral immune response reduction and methods of use thereof |
| CA3077340A1 (en) * | 2017-11-17 | 2019-05-23 | Grifols Diagnostic Solutions Inc. | Novel mammalian expressed human immunodeficiency virus envelope protein antigens |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE373010T1 (de) | 1984-10-18 | 2007-09-15 | Pasteur Institut | Gag-antigen und dessen verwendung zum nachweis von lav-infektion, sowie in immunogenen zusammensetzungen |
| ATE116006T1 (de) | 1985-04-29 | 1995-01-15 | Genetic Systems Corp | Synthetische antigene zum nachweis von aids. |
| US4745055A (en) * | 1985-05-07 | 1988-05-17 | California Biotechnology Inc. | Fused protein for enzyme immunoassay system |
| JP2702911B2 (ja) | 1985-09-11 | 1998-01-26 | ユナイテツド・バイオメデイカル・インコ−ポレ−テツド | 合成ペプチド、並びにそれを用いたエイズおよびプリ・エイズの検出方法 |
| ATE87103T1 (de) | 1985-12-17 | 1993-04-15 | Akzo Nv | Immunochemisches reagenz. |
| US4772547A (en) * | 1986-02-03 | 1988-09-20 | Hoffmann-La Roche Inc. | HTLV-III envelope peptides |
| US4736896A (en) | 1986-02-18 | 1988-04-12 | Hollymatic Corporation | Automatic-feed grinder and meat grinding method |
| WO1987006005A1 (en) | 1986-03-24 | 1987-10-08 | Ortho Pharmaceutical Corporation | Synthetic htlv-iii peptides, compositions and uses thereof |
| US4879212A (en) | 1986-04-02 | 1989-11-07 | United Biomedical Inc. | Peptide composition and method for the detection of antibodies to HTLV-III |
| IE63109B1 (en) | 1986-06-23 | 1995-03-22 | Genetic Systems Corp | Human monoclonal antibody to lymphadenopathy-associated virus |
| WO1988000471A1 (en) | 1986-07-21 | 1988-01-28 | Southwest Foundation For Biomedical Research | Composition of matter and method of immunizing against viral causative agents of aids and arc |
| ES2104556T3 (es) * | 1987-01-16 | 1997-10-16 | Pasteur Institut | Peptidos que tienen propiedades inmunologicas de hiv-2. |
| US4918166A (en) * | 1987-04-10 | 1990-04-17 | Oxford Gene Systems Limited | Particulate hybrid HIV antigens |
| WO1988008005A1 (en) | 1987-04-16 | 1988-10-20 | Johnson & Johnson | Stlv-iii-related polypeptides, diagnostic systems and assay methods |
| DE3727137A1 (de) | 1987-08-14 | 1989-02-23 | Behringwerke Ag | Herstellung von antigenen des human immunodeficiency virus typ 1 sowie deren verwendung als diagnostisches mittel und therapeutikum |
| WO1989001494A1 (en) | 1987-08-21 | 1989-02-23 | Scripps Clinic And Research Foundation | Hiv-1-related polypeptides, diagnostic systems and assay methods |
| SE8704185L (sv) | 1987-10-28 | 1989-04-29 | Ferring Ab | Nya peptider, artificiella antigener och immunoanalystestsatser |
| EP0330359A3 (en) | 1988-02-25 | 1991-06-05 | Bio-Rad Laboratories, Inc. | Composition useful in the diagnosis and treating of hiv-1 infection |
| AU3342689A (en) | 1988-03-24 | 1989-10-16 | Igen Incorporated | Luminescent chimeric proteins |
| AU608413B2 (en) | 1988-03-30 | 1991-03-28 | Abbott Laboratories | Mouse monoclonal antibody (5-21-3) to human immunodeficiency virus gp41 protein |
| EP0362909A3 (en) | 1988-08-26 | 1990-11-14 | Akzo N.V. | Synthetic polypeptides immunochemically reactive with hiv-antibodies |
-
1989
- 1989-12-13 US US07/450,150 patent/US6248574B1/en not_active Expired - Fee Related
-
1990
- 1990-12-13 CA CA002071858A patent/CA2071858A1/en not_active Abandoned
- 1990-12-13 AU AU70333/91A patent/AU653926B2/en not_active Ceased
- 1990-12-13 IL IL96647A patent/IL96647A0/xx unknown
- 1990-12-13 EP EP91901556A patent/EP0509006A1/en not_active Withdrawn
- 1990-12-13 KR KR1019920701393A patent/KR920703102A/ko not_active Withdrawn
- 1990-12-13 JP JP3501964A patent/JPH05503926A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO1991009872A2 (en) | 1991-07-11 |
| AU7033391A (en) | 1991-07-24 |
| EP0509006A1 (en) | 1992-10-21 |
| CA2071858A1 (en) | 1991-06-14 |
| JPH05503926A (ja) | 1993-06-24 |
| IL96647A0 (en) | 1991-09-16 |
| WO1991009872A3 (en) | 1992-04-02 |
| AU653926B2 (en) | 1994-10-20 |
| US6248574B1 (en) | 2001-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5013548A (en) | Production of antibodies to HIV | |
| Gnann Jr et al. | Diagnosis of AIDS by using a 12-amino acid peptide representing an immunodominant epitope of the human immunodeficiency virus | |
| US5019387A (en) | Production of antibodies to HIV | |
| KR910002374B1 (ko) | Aids 관련질병의 검출을 위한 합성항원 | |
| US7070787B2 (en) | Method of inducing the production of antibodies to HIV | |
| EP0245362A4 (en) | SYNTHETIC PEPTIDES AND THEIR USE FOR DIAGNOSIS AND VACCINATION AGAINST AIDS AND ITS ASSOCIATED COMPLEX. | |
| DE3752170T2 (de) | Synthetisches Antigen zum Nachweis von mit AIDS in Zusammenhang stehenden Krankheiten | |
| KR890701742A (ko) | 이형바이러스 펩티드 입자 임뮤노겐 | |
| JPH08511007A (ja) | タンデム合成ｈｉｖ−１ペプチド | |
| NZ230855A (en) | Principal neutralising domain of hiv variant, dna, vaccine, assay, antibodies and treatment | |
| WO1993001210A2 (de) | Hcv peptidantigene und verfahren zur bestimmung von hcv | |
| IL127595A (en) | Polypeptides capable of forming antigen binding structures with specificity for the rhesus d antigens, the dna encoding them and the process for their preparation and use | |
| EP0272858A3 (en) | Recombinant hiv envelope proteins produced in insect cells | |
| RU2337922C9 (ru) | ИЗОЛИРОВАННЫЕ ПОЛИПЕПТИДЫ НА ОСНОВЕ НЕЙТРАЛИЗУЮЩЕГО ЭПИТОПА БЕЛКА p17 ВИРУСА ВИЧ, ИСПОЛЬЗУЕМЫЕ В КАЧЕСТВЕ ВАКЦИН, А ТАКЖЕ НЕЙТРАЛИЗУЮЩИЕ АНТИ-p17-АНТИТЕЛА, СПЕЦИФИЧЕСКИ РАСПОЗНАЮЩИЕ УКАЗАННЫЙ НЕЙТРАЛИЗУЮЩИЙ ЭПИТОП | |
| JP2003525014A5 (ko) | ||
| KR920703102A (ko) | 인간 면역결핍 바이러스(human immunodeficiency virus)에 대한 항체와 선택적으로 반응하는 폴리펩타이드 및 그를 함유하는 백신(vaccines) | |
| EP0572737A3 (en) | Gag-Env fusion antigen from HIV. | |
| EP0582243B2 (de) | HCV Peptidantigene und Verfahren zur Bestimmung von HCV | |
| ATE87487T1 (de) | Rekombinante hiv-2 polypeptide. | |
| US5688914A (en) | Composition containing a B epitope of the envelope glycoprotein of a retrovirus and a T epitope of another distinct protein of this retrovirus | |
| US6080846A (en) | Composition containing a B epitope of the envelope glycoprotein of a retrovirus and a T epitope of another distinct protein of this retrovirus | |
| US5310876A (en) | Expression of HIV1 and HIV2 polypeptides and their use | |
| EP0605433B1 (en) | Immunoassay for the simultaneous detection of hiv-1, hiv-2, htlv-i and htlv-ii antibodies | |
| Richalet-Sécordel et al. | Cross-reactive potential of rabbit antibodies raised against a cyclic peptide representing a chimeric V3 loop of HIV-1 gp120 studied by biosensor technique and ELISA | |
| JP2002522039A5 (ko) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19920612 |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |